Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05512039 · ClinicalTrials.gov registry record · Phase 1
Reduced-dose Botox for Urgency Incontinence Among Elder Females
A Phase 1 study of Overactive Bladder and Urgency Urinary Incontinence, sponsored by Dartmouth-Hitchcock Medical Center.
- Active
- Registry status
- Phase 1
- Development phase
- 376
- Enrollment target
- 7
- Study locations
NCT05512039 is a Phase 1 study of Overactive Bladder and Urgency Urinary Incontinence that is active but no longer recruiting, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 376 participants, above the 203-participant average among 45 other Overactive Bladder trials with a reported enrollment target (85% higher). The trial reports 7 study locations across 7 states.
The verdict
NCT05512039, a Phase 1 study of Overactive Bladder and Urgency Urinary Incontinence, is active but no longer recruiting, sponsored by Dartmouth-Hitchcock Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 376 participants
- Enrollment target
- 7
- Study locations
Study Summary
The purpose of this study is to study the treatment of urgency urinary incontinence (UUI), specifically among women 70 years and older, by comparing reduced versus standard dose of onabotulinumtoxinA (BTX; trade name BOTOX(c)) injection in the bladder.
Conditions Studied
Interventions
- DRUG Botox 50 Unit Injection
- DRUG Botox 100 Unit Injection
Study Locations (7)
Alabama
- University of Alabama - Birmingham - Birmingham
California
- Kaiser Permanente Medical Group - San Diego
Nebraska
- University of Nebraska Medical Center - Omaha
New Hampshire
- Dartmouth-Hitchcock Medical Center - Lebanon
Oregon
- Oregon Health & Science University - Portland
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 376 participants |
| Start Date | 2023-05-12 |
| Est. Completion | 2027-01-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05512039
The ClinicalTrials.gov registry entry for NCT05512039 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 376 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 203-participant average among 45 other Overactive Bladder trials with a reported enrollment target (85% higher). The listed sponsor is Dartmouth-Hitchcock Medical Center, which has 427 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Overactive Bladder appearing as the primary indexed condition, and to 2 interventions - of which Botox 50 Unit Injection is the first listed.
NCT05512039 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Alabama, California, Nebraska.
Frequently Asked Questions
What is clinical trial NCT05512039 about?
NCT05512039 is a clinical study titled "Reduced-dose Botox for Urgency Incontinence Among Elder Females". The purpose of this study is to study the treatment of urgency urinary incontinence (UUI), specifically among women 70 years and older, by comparing reduced versus standard dose of onabotulinumtoxinA (BTX; trade name BOTOX(c)) injection in the bladder.
What is the current status of trial NCT05512039?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 376 participants. The study started on 2023-05-12. Estimated completion is 2027-01-01.
What conditions does trial NCT05512039 study?
This clinical trial studies the following conditions: Overactive Bladder, Urgency Urinary Incontinence, Urinary Incontinence in Old Age.
What interventions are being tested in trial NCT05512039?
The interventions under investigation include: Botox 50 Unit Injection (DRUG), Botox 100 Unit Injection (DRUG).
Who is sponsoring clinical trial NCT05512039?
This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05512039 being conducted?
This trial has 7 study locations across Alabama, California, Nebraska, New Hampshire, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Overactive Bladder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study To Test The Interaction of Two Medications for Treatment of Overactive Bladder
COMPLETED · Phase 1
-
Botulin-A Toxin Instillations and Overactive Bladder
COMPLETED · Phase 1
-
A Two-Part Study to Determine: Best Medication Formulation and Food Effect
COMPLETED · Phase 1
-
Evaluation of the Effect of Dried Cranberry Powder in Women With Dry OAB
COMPLETED · Phase 1
-
Home Versus Office Removal of Percutaneous Nerve Evaluation (PNE) Lead
RECRUITING · NA
-
Bladder Botox UTI Antibiotic Prophylaxis
RECRUITING · Phase 4
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.